Medical Basic Research Innovation Center for Cardiovascular and Cerebrovascular Diseases, Ministry of Education, China, International Joint Laboratory for Drug Target of Critical Illnesses, School of Pharmacy, Nanjing Medical University, Nanjing 211166, China.
Gusu School, Nanjing Medical University, Suzhou Municipal Hospital, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou 215001, China.
J Med Chem. 2023 Nov 9;66(21):14609-14622. doi: 10.1021/acs.jmedchem.3c01090. Epub 2023 Oct 20.
Glioblastoma is the most common brain tumor, with high recurrence and low survival rates. An integrative bioinformatics analysis demonstrated that anaplastic lymphoma kinase (ALK) is a promising therapeutic target for glioblastoma. We designed and synthesized a series of 3-(arylmethylene)indole derivatives, which were further evaluated for antiproliferative activity using glioma cell lines. Among them, compound significantly inhibited the viability of glioblastoma cells. With favorable pharmacokinetic characteristics and blood-brain barrier permeability, improved the survival rate and inhibited the growth of orthotopic glioblastoma. The Phospho-Totum system revealed that ALK was a potential target for the antiglioblastoma activity of . Further experiments indicated that might be a novel ALK modulator, which interacted with the extracellular ligand-binding domain of ALK, thus selectively induced ERK-mediated autophagy and apoptosis. Our findings provide an alternative ALK-based targeting strategy and a new drug candidate for glioblastoma therapy.
胶质母细胞瘤是最常见的脑肿瘤,具有高复发率和低生存率。综合生物信息学分析表明,间变性淋巴瘤激酶(ALK)是胶质母细胞瘤有前途的治疗靶点。我们设计并合成了一系列 3-(芳基亚甲基)吲哚衍生物,并用神经胶质瘤细胞系进一步评估其抗增殖活性。其中,化合物 显著抑制胶质母细胞瘤细胞的活力。化合物 具有良好的药代动力学特性和血脑屏障通透性,可提高存活率并抑制原位胶质母细胞瘤的生长。磷酸化肿瘤系统显示 ALK 是 的抗神经胶质瘤活性的潜在靶点。进一步的实验表明, 可能是一种新型的 ALK 调节剂,它与 ALK 的细胞外配体结合域相互作用,从而选择性地诱导 ERK 介导的自噬和细胞凋亡。我们的研究结果为胶质母细胞瘤治疗提供了一种替代的基于 ALK 的靶向策略和新的候选药物。